(SAN) Sanofi - Ratings and Ratios

Sanofi SA (PA:SAN) is a global healthcare powerhouse with a diverse portfolio spanning pharmaceuticals, vaccines, and consumer healthcare. Operating across the United States, Europe, Canada, and internationally, the company specializes in developing and marketing therapeutic solutions. Its pharmaceutical segment offers a range of specialty care products, including DUPIXENT for atopic dermatitis, treatments for rare blood disorders, oncology, and neurology. The company also provides essential medicines for diabetes and cardiovascular diseases, along with a portfolio of established prescription drugs.

In the vaccines segment, Sanofi covers a broad spectrum of immunization needs. This includes pediatric vaccines such as polio, pertussis, and Hib, as well as a comprehensive range of travel and endemic vaccines like hepatitis A, typhoid, and rabies. Their influenza and meningitis vaccines are particularly notable, addressing both seasonal and endemic threats. This extensive vaccine portfolio underscores Sanofis role in global public health.

The consumer healthcare division offers an array of over-the-counter products tailored to common health needs. These include cough, cold, and flu remedies, allergy treatments, and pain management solutions. Additionally, Sanofi provides products for skin health, addressing conditions like eczema, as well as mental and digestive wellness products. This segment highlights the companys commitment to accessible, everyday health solutions.

Sanofis strategic collaborations are a key driver of innovation. They are working with Exscientia to develop novel small-molecule therapies for oncology and immunology, and with ABL Bio on treatments for neurodegenerative diseases. Partnerships with Blackstone Life Sciences and Seagen Inc. focus on advancing cancer therapies, including antibody-drug conjugates. Collaborations with IGM Biosciences, Skyline Therapeutics, and Adagene further enhance their pipeline in antibody-based therapies and small molecule discoveries. Additionally, agreements with Scribe Therapeutics for genome editing and Provention Bio for teplizumab commercialization showcase their proactive approach to cutting-edge treatments.

Originally known as Sanofi-Aventis, the company rebranded as Sanofi in 2011. Headquartered in Paris, France, since its incorporation in 1994, Sanofi has established itself as a leader in the pharmaceutical industry. Their financials indicate a market capitalization of 129,897 million EUR, with a P/E ratio of 28.86 and a forward P/E of 12.50, suggesting expectations for future growth. A P/S ratio of 2.68 reflects their revenue generation efficiency.